Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Novartis
Medtronic
UBS
Healthtrust
US Army
Fish and Richardson
Colorcon
Chinese Patent Office
Queensland Health

Generated: October 17, 2017

DrugPatentWatch Database Preview

BOEHRINGER INGELHEIM Company Profile

« Back to Dashboard

What is the competitive landscape for BOEHRINGER INGELHEIM, and when can generic versions of BOEHRINGER INGELHEIM drugs launch?

BOEHRINGER INGELHEIM has forty-nine approved drugs.

There are one hundred and three US patents protecting BOEHRINGER INGELHEIM drugs and there have been five Paragraph IV challenges on BOEHRINGER INGELHEIM drugs in the past three years. There is one tentative approval on BOEHRINGER INGELHEIM drugs.

There are two thousand four hundred and seventy-seven patent family members on BOEHRINGER INGELHEIM drugs in sixty-eight countries and one hundred and seventy-eight supplementary protection certificates in fifteen countries.

Summary for Applicant: BOEHRINGER INGELHEIM

International Patents:2477
US Patents:103
Tradenames:40
Ingredients:30
NDAs:49
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
SPIRIVA RESPIMAT
tiotropium bromide
SPRAY, METERED;INHALATION021936-002Sep 15, 2015RXYesNo► Subscribe► SubscribeY► Subscribe
Boehringer Ingelheim
MOBIC
meloxicam
TABLET;ORAL020938-001Apr 13, 2000ABRXYesNo► Subscribe► Subscribe► Subscribe
Boehringer Ingelheim
GLYXAMBI
empagliflozin; linagliptin
TABLET;ORAL206073-001Jan 30, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Boehringer Ingelheim
JENTADUETO XR
linagliptin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208026-001May 27, 2016RXYesNo► Subscribe► SubscribeY ► Subscribe
Boehringer Ingelheim
MIRAPEX
pramipexole dihydrochloride
TABLET;ORAL020667-007Jul 30, 2007ABRXYesNo► Subscribe► Subscribe ► Subscribe
Boehringer Ingelheim
MOBIC
meloxicam
TABLET;ORAL020938-002Aug 23, 2000ABRXYesYes► Subscribe► Subscribe► Subscribe
Boehringer Ingelheim
TRADJENTA
linagliptin
TABLET;ORAL201280-001May 2, 2011RXYesYes► Subscribe► SubscribeY ► Subscribe
Boehringer Ingelheim
PRADAXA
dabigatran etexilate mesylate
CAPSULE;ORAL022512-001Oct 19, 2010RXYesNo► Subscribe► Subscribe ► Subscribe
Boehringer Ingelheim
SPIRIVA RESPIMAT
tiotropium bromide
SPRAY, METERED;INHALATION021936-002Sep 15, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Boehringer Ingelheim
MIRAPEX ER
pramipexole dihydrochloride
TABLET, EXTENDED RELEASE;ORAL022421-001Feb 19, 2010ABRXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Boehringer Ingelheim

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim
MICARDIS
telmisartan
TABLET;ORAL020850-001Nov 10, 1998► Subscribe► Subscribe
Boehringer Ingelheim
MIRAPEX
pramipexole dihydrochloride
TABLET;ORAL020667-002Jul 1, 1997► Subscribe► Subscribe
Boehringer Ingelheim
JENTADUETO
linagliptin; metformin hydrochloride
TABLET;ORAL201281-001Jan 30, 2012► Subscribe► Subscribe
Boehringer Ingelheim
STIOLTO RESPIMAT
olodaterol hydrochloride; tiotropium bromide
SPRAY, METERED;INHALATION206756-001May 21, 2015► Subscribe► Subscribe
Boehringer Ingelheim
CATAPRES-TTS-3
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL018891-003Oct 10, 1984► Subscribe► Subscribe
Boehringer Ingelheim
MIRAPEX ER
pramipexole dihydrochloride
TABLET, EXTENDED RELEASE;ORAL022421-002Feb 19, 2010► Subscribe► Subscribe
Boehringer Ingelheim
STIOLTO RESPIMAT
olodaterol hydrochloride; tiotropium bromide
SPRAY, METERED;INHALATION206756-001May 21, 2015► Subscribe► Subscribe
Boehringer Ingelheim
CATAPRES-TTS-1
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL018891-001Oct 10, 1984► Subscribe► Subscribe
Boehringer Ingelheim
MEXITIL
mexiletine hydrochloride
CAPSULE;ORAL018873-003Dec 30, 1985► Subscribe► Subscribe
Boehringer Ingelheim
ALUPENT
metaproterenol sulfate
AEROSOL, METERED;INHALATION016402-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for BOEHRINGER INGELHEIM drugs

Drugname Dosage Strength Tradename Submissiondate
afatinib dimaleate
Tablets 20 mg, 30 mg and 40 mg 
GILOTRIF
7/12/2017
dabigatran etexilate mesylate
Capsuleseq. to 110 mg base
PRADAXA
12/15/2015
linagliptin
Tablets5 mg
TRADJENTA
5/4/2015
linagliptin and metformin hydrochloride
Tablets2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg
JENTADUETO
5/4/2015
dabigatran etexilate mesylate
Capsuleseq. to 75 mg base and 150 mg base
PRADAXA
10/20/2014
nevirapine
Extended-release Tablets400 mg
VIRAMUNE XR
6/21/2013
pramipexole dihydrochloride
Extended-release Tablets2.25 mg and 3.75 mg
MIRAPEX ER
7/26/2011
pramipexole dihydrochloride
Extended-release Tablets0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg
MIRAPEX ER
6/1/2010
meloxicam
Oral Suspension7.5 mg/5 mL
MOBIC
12/17/2009
telmisartan and hydrochlorothiazide
Tablets80 mg/25 mg
MICARDIS HCT
2/27/2009
telmisartan and hydrochlorothiazide
Tablets80 mg/12.5 mg and 40 mg/12.5 mg
MICARDIS HCT
12/31/2008
pramipexole dihydrochloride
Tablets0.75 mg
MIRAPEX
7/31/2008
aspirin and dipyridamole
Extended-release Capsules25 mg and 200 mg
AGGRENOX
2/1/2007
telmisartan
Tablets20 mg, 40 mg and 80 mg
MICARDIS
12/26/2006
pramipexole dihydrochloride
Tablets0.125 mg, 0.5 mg, 1 mg and 1.5 mg
MIRAPEX
6/24/2005
pramipexole dihydrochloride
Tablets0.25 mg
MIRAPEX
5/27/2005
tamsulosin hydrochloride
Capsules0.4 mg
FLOMAX
12/20/2004

Non-Orange Book Patents for Boehringer Ingelheim

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,414,008 Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions► Subscribe
7,157,429Method of regulating glucose metabolism, and reagents related thereto► Subscribe
7,645,383Microstructured filter► Subscribe
7,820,815Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines► Subscribe
8,318,669Method of regulating glucose metabolism, and reagents related thereto► Subscribe
8,586,608Quinazoline derivatives and pharmaceutical compositions containing them► Subscribe
6,169,181 Compounds useful to treat retroviral infections► Subscribe
8,664,2328-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions► Subscribe
8,404,697Quinazoline derivatives for the treatment of cancer diseases► Subscribe
9,089,571Quinazoline derivatives for the treatment of cancer diseases► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Boehringer Ingelheim Drugs

Country Document Number Estimated Expiration
Poland185669► Subscribe
Colombia5570670► Subscribe
African Regional IP Organization (ARIPO)1572► Subscribe
Japan5813293► Subscribe
Israel144984► Subscribe
Hong Kong1093175► Subscribe
CroatiaP20161061► Subscribe
Iceland7623► Subscribe
Japan2008540373► Subscribe
Canada2275379► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Boehringer Ingelheim Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1730131/01Switzerland► SubscribePRODUCT NAME: EMPAGLIFLOZIN; REGISTRATION NO/DATE: SWISSMEDIC 63227 12.11.2014
437Luxembourg► Subscribe91437, EXPIRES: 20230216
C0049France► SubscribePRODUCT NAME: OLODATEROL, SES ISOMERES OPTIQUES INDIVIDUELS, MELANGES D'ENANTIOMERES INDIVIDUELS OU RACEMATE, SES SELS D'ADDITION D'ACIDE AVEC DES ACIDES PHARMACOLOGIQUEMENT ACCEPTABLES, AINSI QUE DES SOLVATES ET OU HYDRATES, EN PARTICULIER OLODATEROL OU CHLORHYDRATE D'OLODATEROL; NAT. REGISTRATION NO/DATE: NL42395 20140522; FIRST REGISTRATION: MT - MA211/00401 20130918
2014 00064Denmark► SubscribePRODUCT NAME: VILDAGLIPTIN; REG. NO/DATE: EU/1/07/414/001-017 20070926
C/GB02/037United Kingdom► SubscribePRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
C/GB14/084United Kingdom► SubscribePRODUCT NAME: LINAGLIPTIN; REGISTERED: UK EU/1/11/707/001-011 20110830
2014 00062Denmark► SubscribePRODUCT NAME: SAXAGLIPTIN OG FARMACEUTISK SALTE DERAF, HERUNDER SAXAGLIPTIN HYDROCHLORID; REG. NO/DATE: EU/1/09/545/001-015 20091005
90061-7Sweden► SubscribePRODUCT NAME: EMPAGLIFLOZIN AND SALTS THEREOF, IN PARTICULAR EMPAGLIFLOZIN; REG. NO/DATE: EU/1/14/930 20140522
433Luxembourg► SubscribePRODUCT NAME: OLODATEROL,SES ISOMERES OPTIQUES INDIVIDUELS,MELANGES D ENANTIOMERES INDIVIDUELS OU DE RACEMATES,SES SELS D ADDITION D ACIDE AVEC DES ACIDES PHARMACEUTIQUEMENT ACCEPTABLES,AINSI QUE SES SOLVATES ET/OU SES HYDRATES,EN PARTICULIER L OLODATEROL ET LE CHLORHYDRATE D OLODATEROL
00725Netherlands► SubscribePRODUCT NAME: NINTEDANIB, DE TAUTOMEREN DAARVAN EN DE ZOUTEN DAARVAN, IN HET BIJZONDER NINTEDANIB EN FYSIOLOGISCH AANVAARDBARE ZOUTEN DAARVAN, MET NAME NINEDANIBESILAAT; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141121
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Harvard Business School
Moodys
Merck
Federal Trade Commission
Fuji
Novartis
Farmers Insurance
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot